These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 7505775)
21. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645 [TBL] [Abstract][Full Text] [Related]
22. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage. Poulakis V; Witzsch U; De Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E J Urol; 2004 Oct; 172(4 Pt 1):1306-10. PubMed ID: 15371829 [TBL] [Abstract][Full Text] [Related]
23. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Miyake H; Hara I; Kurahashi T; Inoue TA; Eto H; Fujisawa M Clin Cancer Res; 2007 Feb; 13(4):1192-7. PubMed ID: 17317829 [TBL] [Abstract][Full Text] [Related]
25. Is pelvic lymph node dissection required at radical prostatectomy for low-risk prostate cancer? Mitsuzuka K; Koie T; Narita S; Kaiho Y; Yoneyama T; Kawamura S; Tochigi T; Ohyama C; Habuchi T; Arai Y Int J Urol; 2013 Nov; 20(11):1092-6. PubMed ID: 23387553 [TBL] [Abstract][Full Text] [Related]
26. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906 [TBL] [Abstract][Full Text] [Related]
27. Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Godoy G; Chong KT; Cronin A; Vickers A; Laudone V; Touijer K; Guillonneau B; Eastham JA; Scardino PT; Coleman JA Eur Urol; 2011 Aug; 60(2):195-201. PubMed ID: 21257258 [TBL] [Abstract][Full Text] [Related]
28. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. Noguchi M; Stamey TA; McNeal JE; Yemoto CM J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712 [TBL] [Abstract][Full Text] [Related]
29. Detecting lymph nodes metastasis in prostate cancer through extended vs. standard laparoscopic pelvic lymphadenectomy. Arenas LF; Füllhase C; Boemans P; Fichtner J Aktuelle Urol; 2010 Jan; 41 Suppl 1():S10-4. PubMed ID: 20094944 [TBL] [Abstract][Full Text] [Related]
30. Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models. Spevack L; Killion LT; West JC; Rooker GM; Brewer EA; Cuddy PG Int J Radiat Oncol Biol Phys; 1996 Feb; 34(3):543-7. PubMed ID: 8621276 [TBL] [Abstract][Full Text] [Related]
31. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer. Stone NN; Stock RG Mt Sinai J Med; 1999 Jan; 66(1):26-30. PubMed ID: 9989102 [TBL] [Abstract][Full Text] [Related]
32. Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram. Meijer HJ; Debats OA; Roach M; Span PN; Witjes JA; Kaanders JH; van Lin EN; Barentsz JO Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1186-91. PubMed ID: 22520482 [TBL] [Abstract][Full Text] [Related]
33. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy. Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E Urology; 2004 Dec; 64(6):1165-70. PubMed ID: 15596191 [TBL] [Abstract][Full Text] [Related]
34. Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients. Salomon L; Hoznek A; Lefrère-Belda MA; Bellot J; Chopin DK; Abbou CC Eur Urol; 2000 Mar; 37(3):297-300. PubMed ID: 10720855 [TBL] [Abstract][Full Text] [Related]
35. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843 [TBL] [Abstract][Full Text] [Related]
36. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy. Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986 [TBL] [Abstract][Full Text] [Related]
37. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer? Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE Eur Urol; 2006 Aug; 50(2):272-9. PubMed ID: 16632187 [TBL] [Abstract][Full Text] [Related]
38. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. Abdollah F; Klett DE; Sood A; Sammon JD; Pucheril D; Dalela D; Diaz M; Peabody JO; Trinh QD; Menon M BJU Int; 2015 Nov; 116(5):703-12. PubMed ID: 25413443 [TBL] [Abstract][Full Text] [Related]
39. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
40. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]